Capital Counsel LLC NY Has $10.45 Million Stake in Danaher Co. (NYSE:DHR)

Capital Counsel LLC NY reduced its stake in Danaher Co. (NYSE:DHR) by 0.4% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 45,520 shares of the conglomerate’s stock after selling 170 shares during the quarter. Danaher makes up 0.4% of Capital Counsel LLC NY’s investment portfolio, making the stock its 15th largest holding. Capital Counsel LLC NY’s holdings in Danaher were worth $10,449,000 as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Danaher by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 59,750,122 shares of the conglomerate’s stock worth $13,715,641,000 after buying an additional 315,912 shares during the period. Geode Capital Management LLC grew its position in Danaher by 2.4% in the 4th quarter. Geode Capital Management LLC now owns 13,358,206 shares of the conglomerate’s stock worth $3,056,996,000 after purchasing an additional 315,446 shares during the last quarter. Norges Bank bought a new position in shares of Danaher during the 4th quarter worth about $2,130,740,000. Bank of New York Mellon Corp raised its position in shares of Danaher by 5.4% during the fourth quarter. Bank of New York Mellon Corp now owns 8,589,019 shares of the conglomerate’s stock valued at $1,971,609,000 after buying an additional 441,012 shares during the last quarter. Finally, Fisher Asset Management LLC lifted its stake in shares of Danaher by 0.6% in the fourth quarter. Fisher Asset Management LLC now owns 4,578,945 shares of the conglomerate’s stock valued at $1,051,097,000 after buying an additional 26,305 shares during the period. Institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

Shares of DHR stock opened at $186.71 on Friday. The firm has a market cap of $133.44 billion, a price-to-earnings ratio of 35.36, a PEG ratio of 2.66 and a beta of 0.86. Danaher Co. has a 12 month low of $171.00 and a 12 month high of $281.70. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. The stock has a 50-day moving average price of $202.28 and a 200 day moving average price of $227.84.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, meeting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period last year, the company earned $2.09 EPS. Research analysts expect that Danaher Co. will post 7.63 EPS for the current year.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.69%. The ex-dividend date of this dividend is Friday, March 28th. This is an increase from Danaher’s previous quarterly dividend of $0.27. Danaher’s dividend payout ratio is currently 24.24%.

Insiders Place Their Bets

In related news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 11.10% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on DHR shares. Robert W. Baird set a $231.00 price target on Danaher in a report on Wednesday. Scotiabank started coverage on Danaher in a research report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 target price for the company. Raymond James reissued a “market perform” rating on shares of Danaher in a report on Monday, February 3rd. The Goldman Sachs Group raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $260.00 price objective for the company in a report on Friday, March 21st. Finally, Barclays upgraded shares of Danaher from an “equal weight” rating to an “overweight” rating and decreased their target price for the company from $240.00 to $205.00 in a research report on Thursday, April 10th. Four research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $274.55.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.